Pernix Therapeutics (PTX) Reports Q2 Loss of $0.47/Share

Pernix Therapeutics (NASDAQ: PTX) reported Q2 EPS of ($0.47), versus ($0.62) reported last year. Revenue for the quarter came in at $36.75 million, versus $46.98 million reported last year.

For earnings history and earnings-related data on Pernix Therapeutics (PTX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
• Boost Run, Inc. (BRUN) Reports Q2 Revenue of $31.1M